Background. 2018 Guideline from the College of American Pathologists(CAP), the International Association for the Study of Lung Cancer (IASLC) , and the Association for Molecular Pathology(AMP) established a benchmark turnaround time (TAT), according to which the results were supposed to be available to the treating oncologist within 10 working days. Methods. In this study, we established and validated a new protocol for pathological diagnosis and treatment pathway that was tested in the Henan Cancer Hospital, China. Results. Compared with the routine pathway, the new path adopts a parallel approach to conventional pathology and molecular pathology, which significantly shortens the TAT to 4-6 days. Self-designed DNA biology collector “BIOCO” tool, designed by our team to collect specimens that are discarded when the wax block is trimmed, can effectively save pathological samples, avoid cross-contamination and reduce the period extension caused by re-sampling. Most importantly, its accuracy and effectiveness are consistent with conventional collection methods. Conclusions. Therefore, the new diagnosis and treatment pathway based on the BIOCO collector can be used as a practical approach to the molecular diagnostic platform of the hospital pathology department.